Benefits Think Is GLP-1 coverage actually delivering value?

Published 5 Min Read

Hand holding Ozempic injection pen for diabetes treatment.
Adobe Stock

For the past few years, benefits consultants have spent considerable energy helping employers understand and navigate the dynamic GLP-1 landscape. It’s a space moving faster than most can keep up with: new drugs entering the market, new indications and mounting cost pressures. 

Initially, employers grappled with the dilemma of whether to cover GLP-1s. Notably, the conversation has shifted with employers and benefits leaders are now trending in favor of coverage, settling this conundrum.


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form